HRP20150552T1 - Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom - Google Patents
Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom Download PDFInfo
- Publication number
- HRP20150552T1 HRP20150552T1 HRP20150552TT HRP20150552T HRP20150552T1 HR P20150552 T1 HRP20150552 T1 HR P20150552T1 HR P20150552T T HRP20150552T T HR P20150552TT HR P20150552 T HRP20150552 T HR P20150552T HR P20150552 T1 HRP20150552 T1 HR P20150552T1
- Authority
- HR
- Croatia
- Prior art keywords
- molecule
- use according
- ctla4
- immunoglobulin
- amino acid
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 title 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 8
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 3
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 3
- 210000000707 wrist Anatomy 0.000 claims 3
- 241000282693 Cercopithecidae Species 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010051763 Bone marrow oedema Diseases 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023232 Joint swelling Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 210000002411 hand bone Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Claims (13)
1. Molekula CTLA4, pri čemu CTLA4 molekula veže CD80 i/ili CD86 i obuhvaća vanstaničnu domenu CTLA4 prikazanu slijedom identifikacijskog broja SEQ ID NO:2 koja počinje alaninom na poziciji 26 ili metioninom na poziciji 27 i završava asparaginskom kiselinom na poziciji 150, za uporabu u liječenju nediferenciranog artritisa (UA).
2. Molekula za uporabu iz patentnog zahtjeva 1, pri čemu CTLA4 molekula nadalje obuhvaća slijed aminokiselina koji mijenja topljivost ili afinitet CTLA4 molekule.
3. Molekula za uporabu iz patentnog zahtjeva 2, pri čemu slijed aminokiselina koji mijenja topljivost ili afinitet obuhvaća imunoglobulin.
4. Molekula za uporabu iz patentnog zahtjeva 3, pri čemu je imunoglobulin konstantna regija imunoglobulina ili njen dio.
5. Molekula za uporabu iz patentnog zahtjeva 4, pri čemu su konstantna regija imunoglobulina ili njen dio mutirani zbog smanjenja efektorske funkcije.
6. Molekula za uporabu iz patentnog zahtjeva 4, pri čemu konstantna regija imunoglobulina ili njen dio obuhvaćaju zglob, CH2 i CH3 regije ljudske ili majmunske molekule imunoglobulina.
7. Molekula za uporabu iz patentnog zahtjeva 5, pri čemu konstantna regija imunoglobulina ili njen dio obuhvaćaju zglob, CH2 i CH3 regije ljudske ili majmunske molekule imunoglobulina.
8. Molekula za uporabu iz patentnog zahtjeva 1, pri čemu CTLA4 molekula obuhvaća:
a) Slijed aminokiselina koji počinje metioninom na poziciji 27 i završava lizinom na poziciji 383 slijeda identifikacijskog broja SEQ ID NO:2, ili
b) Slijed aminokiselina koji počinje alaninom na poziciji 26 i završava lizinom na poziciji 383 slijeda identifikacijskog broja SEQ ID NO:2
9. Molekula za uporabu iz patentnog zahtjeva 1 ili patentnog zahtjeva 8, za ublažavanje simptoma UA.
10. Molekula za uporabu iz patentnog zahtjeva 9, pri čemu je simptom odabran iz grupe koja se sastoji od oteklina zglobova, osjetljivosti zglobova, upale, jutarnje zakočenosti i boli.
11. Molekula za uporabu iz bilo kojeg od patentnih zahtjeva 1 do 8, pri čemu je molekula CTLA4 topljiva fuzijska CTLA4 molekula koja je za primjenu podložnim osobama u količini od 10 mg/kg težine podložne osobe.
12. Molekula za uporabu iz patentnog zahtjeva 1 ili patentnog zahtjeva 8 za inhibiranje strukturnog oštećenja.
13. Molekula za uporabu iz patentnog zahtjeva 12, pri čemu je strukturno oštećenje odabrano iz grupe koja se sastoji od erozije ručnog zgloba i ruke, edema koštane srži u ručnom zglobu i ruci, sinovitisa u ručnom zglobu i ruci.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5033608P | 2008-05-05 | 2008-05-05 | |
| US12/387,359 US7915222B2 (en) | 2008-05-05 | 2009-05-01 | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| EP20090743410 EP2279206B1 (en) | 2008-05-05 | 2009-05-05 | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| PCT/US2009/042761 WO2009137424A1 (en) | 2008-05-05 | 2009-05-05 | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150552T1 true HRP20150552T1 (hr) | 2015-06-19 |
Family
ID=41264941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150552TT HRP20150552T1 (hr) | 2008-05-05 | 2015-05-25 | Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7915222B2 (hr) |
| EP (2) | EP2891665A1 (hr) |
| JP (1) | JP2011522795A (hr) |
| KR (1) | KR20110014180A (hr) |
| CN (1) | CN102037010A (hr) |
| AR (1) | AR071672A1 (hr) |
| AU (1) | AU2009244448B2 (hr) |
| BR (1) | BRPI0912249A2 (hr) |
| CA (1) | CA2723698C (hr) |
| CL (1) | CL2009001082A1 (hr) |
| DK (1) | DK2279206T3 (hr) |
| EA (1) | EA201001749A1 (hr) |
| ES (1) | ES2539840T3 (hr) |
| HK (2) | HK1148291A1 (hr) |
| HR (1) | HRP20150552T1 (hr) |
| HU (1) | HUE025256T2 (hr) |
| IL (1) | IL208691A (hr) |
| MX (1) | MX2010011503A (hr) |
| NZ (1) | NZ589020A (hr) |
| PL (1) | PL2279206T3 (hr) |
| PT (1) | PT2279206E (hr) |
| SI (1) | SI2279206T1 (hr) |
| TW (2) | TW201444575A (hr) |
| WO (1) | WO2009137424A1 (hr) |
| ZA (1) | ZA201007914B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| JP6239517B2 (ja) * | 2011-10-10 | 2017-11-29 | メディミューン リミテッド | 関節リウマチの治療法 |
| US20140006055A1 (en) * | 2012-06-27 | 2014-01-02 | Iagnosis, Inc. | Integrated Medical Evaluation and Record Keeping System |
| WO2014070840A2 (en) * | 2012-10-30 | 2014-05-08 | Emory University | Stimulating bone formation by inhibition of cd28 co-stimulation |
| WO2014151230A2 (en) * | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Method of treating granulomatosis with polyangiitis |
| AU2015249656A1 (en) * | 2014-04-25 | 2016-11-03 | Bristol-Myers Squibb Company | Use of CTLA4 compound for achieving drug-free remission in subjects with early RA |
| KR20240046641A (ko) | 2015-04-17 | 2024-04-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 조율가능한 친화성을 갖는 면역조절 단백질 |
| MA50360A (fr) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
| CN110148465B (zh) * | 2019-05-10 | 2023-07-04 | 中山大学孙逸仙纪念医院 | 一种用于分析类风湿性关节炎的系统 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580756A (en) * | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
| US7070776B1 (en) * | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| DE122007000078I2 (de) * | 1991-06-27 | 2011-01-13 | Bristol Myers Squibb Co | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| CA2154487A1 (en) * | 1993-01-21 | 1994-08-04 | Nicholas S. Hill | Vaccines and methods for preventing and treating fescue toxicosis in herbivores |
| US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| EP0892643B2 (en) * | 1996-03-20 | 2009-09-02 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
| US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| KR20030007899A (ko) * | 2000-06-09 | 2003-01-23 | 브리스톨-마이어스스퀴브컴파니 | 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법 |
| US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| TWI322153B (en) * | 2000-07-03 | 2010-03-21 | Bristol Myers Squibb Co | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| AU2002243905B2 (en) * | 2001-01-26 | 2007-11-08 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| PL204899B1 (pl) * | 2001-05-23 | 2010-02-26 | Bristol Myers Squibb Co | Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4 |
| WO2004058800A2 (en) * | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| ES2354610T5 (es) * | 2002-12-23 | 2020-09-14 | Bristol Myers Squibb Co | Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína |
| BRPI0413326A (pt) * | 2003-08-04 | 2006-10-10 | Bristol Myers Squibb Co | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel |
| JP5058991B2 (ja) | 2005-06-29 | 2012-10-24 | コンプメディクス リミテッド | 導電ブリッジを備えるセンサ・アセンブリ |
| WO2007024964A1 (en) * | 2005-08-22 | 2007-03-01 | Incept, Llc | Flared stents and apparatus and methods for making and using them |
| PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
| CN101822820A (zh) | 2005-12-20 | 2010-09-08 | 布里斯托尔—迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
| US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
| US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
-
2009
- 2009-05-01 US US12/387,359 patent/US7915222B2/en active Active
- 2009-05-05 ES ES09743410.4T patent/ES2539840T3/es active Active
- 2009-05-05 AR ARP090101621A patent/AR071672A1/es unknown
- 2009-05-05 BR BRPI0912249A patent/BRPI0912249A2/pt not_active Application Discontinuation
- 2009-05-05 EP EP15152246.3A patent/EP2891665A1/en not_active Withdrawn
- 2009-05-05 WO PCT/US2009/042761 patent/WO2009137424A1/en active Application Filing
- 2009-05-05 CA CA2723698A patent/CA2723698C/en active Active
- 2009-05-05 TW TW103129409A patent/TW201444575A/zh unknown
- 2009-05-05 HU HUE09743410A patent/HUE025256T2/en unknown
- 2009-05-05 PT PT97434104T patent/PT2279206E/pt unknown
- 2009-05-05 DK DK09743410.4T patent/DK2279206T3/en active
- 2009-05-05 CL CL2009001082A patent/CL2009001082A1/es unknown
- 2009-05-05 AU AU2009244448A patent/AU2009244448B2/en not_active Ceased
- 2009-05-05 MX MX2010011503A patent/MX2010011503A/es active IP Right Grant
- 2009-05-05 EP EP20090743410 patent/EP2279206B1/en active Active
- 2009-05-05 JP JP2011508582A patent/JP2011522795A/ja active Pending
- 2009-05-05 NZ NZ589020A patent/NZ589020A/en not_active IP Right Cessation
- 2009-05-05 TW TW098114831A patent/TWI454278B/zh not_active IP Right Cessation
- 2009-05-05 KR KR1020107027221A patent/KR20110014180A/ko not_active Application Discontinuation
- 2009-05-05 PL PL09743410T patent/PL2279206T3/pl unknown
- 2009-05-05 SI SI200931228T patent/SI2279206T1/sl unknown
- 2009-05-05 CN CN2009801162049A patent/CN102037010A/zh active Pending
- 2009-05-05 EA EA201001749A patent/EA201001749A1/ru unknown
-
2010
- 2010-10-13 IL IL208691A patent/IL208691A/en not_active IP Right Cessation
- 2010-11-04 ZA ZA2010/07914A patent/ZA201007914B/en unknown
-
2011
- 2011-02-10 US US13/024,601 patent/US8435952B2/en active Active
- 2011-03-07 HK HK11102241.0A patent/HK1148291A1/xx unknown
- 2011-03-07 HK HK15108768.6A patent/HK1208230A1/xx unknown
-
2013
- 2013-03-27 US US13/851,166 patent/US9012408B2/en active Active
-
2015
- 2015-05-25 HR HRP20150552TT patent/HRP20150552T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150552T1 (hr) | Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom | |
| JP2011522795A5 (hr) | ||
| Harding et al. | Obesity is associated with higher absolute tibiofemoral contact and muscle forces during gait with and without knee osteoarthritis | |
| RS54299B1 (en) | COMPOSITIONS AND METHODS OF USING THERAPY ANTIBODIES | |
| Tzartos et al. | Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. | |
| Fowler et al. | The effect of lower extremity selective voluntary motor control on interjoint coordination during gait in children with spastic diplegic cerebral palsy | |
| JP2019507589A5 (hr) | ||
| Matsuo et al. | Asymmetric load-carrying in young and elderly women: Relationship with lower limb coordination | |
| HRP20130877T1 (hr) | Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena | |
| RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| Buckley et al. | Age impairs sit-to-walk motor performance | |
| JP2010529957A5 (hr) | ||
| HRP20141111T1 (hr) | Sastav her2-protutijela | |
| PE20190743A1 (es) | Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib | |
| BRPI0821266B8 (pt) | Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica | |
| JP2009529915A5 (hr) | ||
| HRP20231645T1 (hr) | T stanični receptori | |
| ES2724364T3 (es) | Procedimiento de tratamiento de fibrosis pulmonar idiopática | |
| Rist et al. | Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptor | |
| Wada et al. | The correlation between movement of the center of mass and the kinematics of the spine, pelvis, and hip joints during body rotation | |
| JP2019506408A5 (hr) | ||
| EA201290028A1 (ru) | Однодоменные антитела против рецептора tgf-бета ii типа | |
| KR20060065588A (ko) | 면역 조절 활성, 항염증 활성 및 항바이러스 활성을 지니는펩티드 및 펩티도미메틱 | |
| CN110914294A (zh) | 重组卵泡抑素-fc融合蛋白及其在治疗杜氏肌营养不良中的用途 | |
| CA2529555A1 (en) | Leukocyte internalized peptide-drug conjugates |